Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

nancial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performa
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... JOLLA, Calif. , Nov. 26, 2014   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and CEO of Regulus, ... Annual Piper Jaffray Healthcare Conference at the New ... 2:00 p.m. EST.  The presentation will be webcast at ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
(Date:11/26/2014)... 26, 2014 The medical magnetic resonance ... of 4%, with world market revenues for 2013 ... and other types of medical imaging have led ... numerous medical conditions in children and adults, each ... report, Medical Imaging Markets , analyzes the ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... ... of Body Mass Index -, PHILADELPHIA, Oct. 16 ... been,established, but healthcare professionals have had little guidance as to,whether ... with GERD. Two studies about obesity and its,relationship to GERD ...
... to File Supplemental New Drug Application with FDA in First ... ... FRANCISCO, Calif., Oct. 16 Anesiva,Inc. (Nasdaq: ANSV ) today ... randomized, double-blind study,with 699 adult patients met its primary endpoint, demonstrating ...
Cached Medicine Technology:Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 2Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 3Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 4Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 5Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 2Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 3Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 4Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 5
(Date:11/27/2014)... 28, 2014 One of the ... The market for implant dentistry comprises dental implants ... global market for dental care is bifurcated into ... dental equipment segment is composed of large equipment. ... at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The worldwide dental ...
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its collection ... media player promotion for Dec. 2014. , The CEO ... in April, and this promotion will help to expand our ... models on our website, she/he can contact us with special ... models come in the latest designs, and they actually are ...
(Date:11/27/2014)... Turks and Caicos Islands; BWI (PRWEB) November 28, 2014 ... for the Tuscany Resort in the Turks & Caicos. ... resorts by TripAdvisor in Providenciales, is announcing a few ... three bedroom villa rentals. And they are offering ... resort. , Additionally, The Tuscany, is having a ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading ... in place to counter this. However, it doesn’t seem ... with menstrual blood are taken as seriously. , ... way to handle tampons and menstrual pads while also ... , He then created a prototype of the Sani-M, ...
Breaking Medicine News(10 mins):Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2
... PHILADELPHIA A research team led by Nancy Speck, ... Perelman School of Medicine at the University of Pennsylvania, ... of hematopoietic (blood) stem cells (HSCs) in the developing ... from engineered precursors., Because HSCs, found in the bone ...
... FOR DEC. 9, 2011] The investigation of a 2009 ... (STEC), an important cause of bacterial gastrointestinal illness, led ... Published in Clinical Infectious Diseases and ... offers recommendations for prevention, including a stronger message for ...
... ANTONIO -- Precisely quantifying the amount of three different ... linked to breast cancer , did not predict ... Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive ... human epidermal growth factor receptor 2 that promotes cancer ...
... quarter century of work in Malawi, a Michigan State ... MRI scans on children newly diagnosed with cerebral malaria ... Michael Potchen, an associate professor in the Department ... from the Dana Foundation, a private philanthropic organization supporting ...
... may help personalize pain medication management for sickle cell ... Dr. Cheedy Jaja, a nurse research scientist and ... National Institutes of Health grant to determine if variations ... opioids could help physicians manage sickle cell pain. ...
... blood test with other factors including the size of the ... up to one-quarter of men avoid biopsies and the risks ... team says. Writing in a study published online by ... G. Sanda, MD, Director of the Prostate Center at Beth ...
Cached Medicine News:Health News:Penn study unlocks origins of blood stem cells 2Health News:Ready-to-bake cookie dough not ready-to-eat, study of E. coli outbreak finds 2Health News:Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer 2Health News:Uncovering how cerebral malaria damages the brain 2Health News:Study probes genetic link to sickle cell pain management 2Health News:Study probes genetic link to sickle cell pain management 3Health News:Study probes genetic link to sickle cell pain management 4Health News:PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies 2Health News:PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: